Johnson & Johnson s worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients claims that J&J talc products caused cancer.
The new guideline replaces 2017 guidance after new evidence from multiple large trials emerged, indicating comparable outcomes with partial and whole breast radiation.
The fast pace of progress in endometrial cancer has taken a step forward with two trials underlining the benefit of immunotherapy plus chemo, while suggesting adding a PARP inhibitor could further boost outcomes.